ONCY
Price:
$0.958
Market Cap:
$100.07M
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgar...[Read more]
Industry
Biotechnology
IPO Date
2001-10-05
Stock Exchange
NASDAQ
Ticker
ONCY
According to Oncolytics Biotech Inc.’s latest financial reports and current stock price. The company's current ROE is -114.55%. This represents a change of 287.73% compared to the average of -29.54% of the last 4 quarters.
The mean historical ROE of Oncolytics Biotech Inc. over the last ten years is 4.11%. The current -114.55% ROE has changed -102.79% with respect to the historical average. Over the past ten years (40 quarters), ONCY's ROE was at its highest in in the December 2019 quarter at 17.98%. The ROE was at its lowest in in the June 2019 quarter at -138.70%.
Average
4.11%
Median
-97.20%
Minimum
-275.00%
Maximum
42.22%
Discovering the peaks and valleys of Oncolytics Biotech Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 154.66%
Maximum Annual ROE = 42.22%
Minimum Annual Increase = -15452.60%
Minimum Annual ROE = -275.00%
Year | ROE | Change |
---|---|---|
2023 | -100.69% | 7.44% |
2022 | -93.71% | 28.60% |
2021 | -72.87% | -7.75% |
2020 | -78.98% | -100.19% |
2019 | 42.22% | -15452.60% |
2018 | -275.00% | 45.87% |
2017 | -188.52% | 33.11% |
2016 | -141.63% | 154.66% |
2015 | -55.62% | -58.72% |
2014 | -134.74% | 27.18% |
The current ROE of Oncolytics Biotech Inc. (ONCY) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-89.09%
5-year avg
8.37%
10-year avg
4.11%
Oncolytics Biotech Inc.’s ROE is greater than scPharmaceuticals Inc. (-201.84%), greater than Milestone Pharmaceuticals Inc. (-165.26%), less than Seres Therapeutics, Inc. (313.56%), greater than aTyr Pharma, Inc. (-56.83%), greater than DiaMedica Therapeutics Inc. (-38.56%), greater than Inhibikase Therapeutics, Inc. (-194.17%), less than X4 Pharmaceuticals, Inc. (0%), less than Galera Therapeutics, Inc. (32.93%), less than Terns Pharmaceuticals, Inc. (21.95%), greater than Day One Biopharmaceuticals, Inc. (-39.58%), greater than HOOKIPA Pharma Inc. (-122.70%), greater than CureVac N.V. (-51.77%), greater than Reata Pharmaceuticals, Inc. (-56.93%), less than Krystal Biotech, Inc. (19.32%), less than Vir Biotechnology, Inc. (13.36%), greater than Propanc Biopharma, Inc. (-30.93%), less than null (70.39%),
Company | ROE | Market cap |
---|---|---|
-201.84% | $255.65M | |
-165.26% | $77.77M | |
313.56% | $145.36M | |
-56.83% | $131.12M | |
-38.56% | $172.27M | |
-194.17% | $10.00M | |
0% | $109.78M | |
32.93% | $4.08M | |
21.95% | $549.60M | |
-39.58% | $1.25B | |
-122.70% | $159.50M | |
-51.77% | $614.60M | |
-56.93% | $6.57B | |
19.32% | $5.29B | |
13.36% | $1.06B | |
-30.93% | $278.87K | |
70.39% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncolytics Biotech Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Oncolytics Biotech Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Oncolytics Biotech Inc.'s ROE?
How is the ROE calculated for Oncolytics Biotech Inc. (ONCY)?
What is the highest ROE for Oncolytics Biotech Inc. (ONCY)?
What is the 3-year average ROE for Oncolytics Biotech Inc. (ONCY)?
What is the 5-year average ROE for Oncolytics Biotech Inc. (ONCY)?
How does the current ROE for Oncolytics Biotech Inc. (ONCY) compare to its historical average?